SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-24-020264
Filing Date
2024-12-11
Accepted
2024-12-11 16:30:34
Documents
59
Period of Report
2024-10-31

Document Format Files

Seq Description Document Type Size
1 p12624510q.htm   iXBRL 10-Q 877225
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 7827
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7612
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 5009
  Complete submission text file 0001214659-24-020264.txt   4273823

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzm-20241031.xsd EX-101.SCH 37580
6 XBRL CALCULATION FILE alzm-20241031_cal.xml EX-101.CAL 32055
7 XBRL DEFINITION FILE alzm-20241031_def.xml EX-101.DEF 121897
8 XBRL LABEL FILE alzm-20241031_lab.xml EX-101.LAB 309488
9 XBRL PRESENTATION FILE alzm-20241031_pre.xml EX-101.PRE 248271
61 EXTRACTED XBRL INSTANCE DOCUMENT p12624510q_htm.xml XML 564958
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 241541935
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)